Ariana raises venture funds for decision tool
This article was originally published in Scrip
Ariana Pharma has raised its first round of venture financing, €1.5 million from Vizille Capital Innovation. VCI will take a minority stake in the decision tool developer alongside existing shareholders, Institut Pasteur and company management. Ariana, which has been mainly self-funding until now, has established a growing software business through collaboration and licensing agreements with pharmaceutical companies, such as Pfizer, GlaxoSmithKline, Novartis and Lundbeck. Its lead product is KEM (Knowledge Extraction and Management), a data mining tool. The new funding will be used to strengthen the company's sales and marketing infrastructure, and for further development work to add functionality to KEM that will enhance its use in clinical trials and drug safety domains. Ariana was founded in 2003 and is headquartered in Paris, France.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.